<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04453813</url>
  </required_header>
  <id_info>
    <org_study_id>SYSUCC-MYC-2020-2101</org_study_id>
    <nct_id>NCT04453813</nct_id>
  </id_info>
  <brief_title>Toripalimab Plus Concurrent Chemo-radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma</brief_title>
  <official_title>A Multicenter Randomized Clinical Phase 3 Trial of Toripalimab Plus Concurrent Chemo-radiotherapy vs Concurrent Chemo-radiotherapy Alone for Unresectable Locally Recurrent Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Affiliated Cancer Hospital &amp; Institute of Guangzhou Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhongshan People's Hospital, Guangdong, China</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yuebei People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wuzhou Red Cross Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fifth Affiliated Hospital, Sun Yat-Sen University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that
      concurrent and adjuvant PD-1 treatment added to concurrent chemo-radiotherapy could further
      decrease the rate of disease progression and improve the survival outcome of patients with
      unresectable locally recurrent nasopharyngeal carcinoma compared with those treated with
      concurrent chemo-radiotherapy alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Through multicenter, open-label, randomised clinical trials, patients with unresectable
      locally recurrent nasopharyngeal carcinoma are randomized into concurrent chemo-radiotherapy
      plus concurrent and adjuvant PD-1 treatment group and concurrent chemo-radiotherapy alone
      group. The efficacy and safety of patients between these two groups are compared.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 3, 2020</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">July 2025</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progress-free survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as time from randomization to locoregional or distant metastasis relapse or death from any cause, whichever occurred first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the time interval from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Metastasis-Free Survival (DMFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the time interval from randomisation to the date of first distant metastases.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Locoregional Relapse-Free Survival (LRRFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the time from randomisation to the date of first locoregional relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment related acute complications</measure>
    <time_frame>up to 1 years</time_frame>
    <description>The proportion of patients with treatment related acute complications according to NCI-CTC5.0 criteria and RTOG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment related late complications</measure>
    <time_frame>up to 3 years</time_frame>
    <description>The proportion of patients with treatment related late complications according to NCI-CTC5.0 criteria and RTOG criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Score of survival quality according to the EORTC Quality of Life Questionnaire (QLQ)-C30 (V3.0) before treatment, during treatment, after treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&amp;N35)</measure>
    <time_frame>up to 3 years</time_frame>
    <description>Score of survival quality according to the EORTC Quality of Life Questionnaire Head and Neck (The QLQ-H&amp;N35) before treatment, during treatment, after treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">226</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Chemotherapy</condition>
  <condition>Radiotherapy</condition>
  <condition>PD-1 Treatment</condition>
  <arm_group>
    <arm_group_label>Toripalimab plus concurrent chemo-radiotherapy arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Concurrent chemo-radiotherapy plus concurrent and adjuvant toripalimab.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Concurrent chemo-radiotherapy arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Concurrent chemo-radiotherapy alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab plus concurrent chemo-radiotherapy</intervention_name>
    <description>Toripalimab: 240 mg, intravenous injection over 60 minutes (Q3W); 2 cycles of toripalimab are concurrently used during radiotherapy and other 9 cycles of toripalimab are used after the end of radiotherapy. (A total of 11 cycles).
Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.
IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy</description>
    <arm_group_label>Toripalimab plus concurrent chemo-radiotherapy arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Concurrent chemo-radiotherapy</intervention_name>
    <description>Concurrent cisplatin chemotherapy: cisplatin is given at a dose of 100 mg/m2 via a continuous intravenous infusion during radiotherapy and starts on the 1st day of radiotherapy for 2 cycles. 1 cycles per 3 weeks.
IMRT: PTVnx#60.0Gy/27Fr/2.22Gy; PTVnd# 60-64Gy/27Fr/2.22-2.37Gy; PTV1#54Gy/27Fr/2.00Gy</description>
    <arm_group_label>Concurrent chemo-radiotherapy arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically confirmed recurrent nasopharyngeal carcinoma.

          2. The recurrence time is more than 12 months from the end of the first course of
             radiotherapy.

          3. Tumor staged as rT2-4N0-3M0，rII-IVa (according to the 8th AJCC edition).

          4. Subjects must have a measurable disease by CT or MRI per RECIST 1.1 criteria.

          5. Karnofsky scale (KPS)≥70.

          6. Normal bone marrow function.

          7. Normal liver and kidney function:

               1. total bilirubin, AST and ALT levels of no more than 2.5 times the upper normal
                  limit;

               2. creatinine clearance rate of at least 60 mL/min or creatinine of no more than 1.5
                  times the upper normal limit.

          8. Given written informed consent.

        Exclusion Criteria:

          1. Resectable nasopharyngeal diseases: rT2 (the tumour is confined in the superficial
             parapharyngeal spacer and is more than 0.5cm from the internal carotid artery) and rT3
             (the tumour is confined in the base wall of the sphenoid sinus and is more than 0.5cm
             from the internal carotid artery and cavernous sinus).

          2. The patients are suffering from severe nasopharyngeal necrosis, radiation induced
             brain injury, and fibrosis of the neck et. al, who are evaluated as unsuitable for
             secondary radiotherapy by the researchers.

          3. Has known allergy to large molecule protein products or any compound of study therapy.

          4. Has known subjects with other malignant tumors.

          5. Has any active autoimmune disease or history of autoimmune disease.

          6. Has a history of psychiatric substance abuse, alcoholism, or drug addiction.

          7. The laboratory examination value does not meet the relevant standards within 7 days
             before enrollment

          8. Received a systematic glucocorticoid therapy within 4 weeks of the first dose of study
             medication.

          9. Has a known history of active TB (bacillus tuberculosis) within 1 year; patients with
             adequately treated active TB with 1 year.

         10. Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1) or CTLA-4 agent.

         11. Has active autoimmune disease (e.g., uveitis, enteritis, hepatitis, hypophysitis,
             nephritis, vasculitis, hyperthyroidism, and asthma requiring bronchodilator therapy).
             Patients with skin disease that doesn't require systemic treatment (e.g., vitiligo,
             psoriasis, or alopecia) will be allowed to enroll.

         12. Has a known history of human immunodeficiency virus (HIV).

         13. Has hepatitis B surface antigen (HBsAg) positive with HBV DNA copy number of
             ≥1000cps/ml or hepatitis C virus (HCV) antibody positive

         14. Has received a live vaccine within 4 weeks of planned start of study therapy

         15. Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ming-Yuan Chen, MD, PhD</last_name>
    <phone>: 86-20-87343624</phone>
    <email>chmingy@mail.sysu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rui You, MD, PhD</last_name>
    <phone>86-13580439820</phone>
    <email>yourui@sysucc.org.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ming-Yuan Chen, MD, PhD</last_name>
      <phone>86-20-8734-3361</phone>
      <email>chmingy@mail.sysu.edu.cn</email>
    </contact>
    <investigator>
      <last_name>Ming-Yuan Chen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Center of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510095</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dong-Ping Chen, MD</last_name>
      <phone>86-13302215492</phone>
      <email>chen_dpgz@163.com</email>
    </contact>
    <investigator>
      <last_name>Dong-Ping Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yuebei People's Hospital</name>
      <address>
        <city>Shaoguan</city>
        <state>Guangdong</state>
        <zip>512025</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Su-Ming Pan, MD</last_name>
      <phone>86-13826331948</phone>
    </contact>
    <investigator>
      <last_name>Su-Ming Pan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Zhongshan People's Hospital</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <zip>528403</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Lei, MD</last_name>
      <phone>86-18933345382</phone>
      <email>13528227676@163.com</email>
    </contact>
    <investigator>
      <last_name>Feng Lei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Fifth Affiliated Hospital of Sun Yat-sen University</name>
      <address>
        <city>Zhuhai</city>
        <state>Guangdong</state>
        <zip>519000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zhi-Gang Liu, MD, PhD</last_name>
      <phone>86-18627585860</phone>
    </contact>
    <investigator>
      <last_name>Zhi-Gang Liu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wuzhou Red Cross Hospital</name>
      <address>
        <city>Wuzhou</city>
        <state>Guangxi</state>
        <zip>543002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jin-Hui Liang, MD</last_name>
      <phone>86-13878480806</phone>
    </contact>
    <investigator>
      <last_name>Jin-Hui Liang, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>June 27, 2020</study_first_submitted>
  <study_first_submitted_qc>June 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 1, 2020</study_first_posted>
  <last_update_submitted>July 3, 2020</last_update_submitted>
  <last_update_submitted_qc>July 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Ming-Yuan Chen</investigator_full_name>
    <investigator_title>Professor, Chief Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

